Antibody Discovery News and Research

RSS
arGEN-X collaborates with Bayer Pharma for development of therapeutic antibodies

arGEN-X collaborates with Bayer Pharma for development of therapeutic antibodies

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric modulator antibodies

Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric modulator antibodies

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

BioInvent International receives US patent for drug discovery technology F.I.R.S.T.

BioInvent International receives US patent for drug discovery technology F.I.R.S.T.

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

TSRI scientists find way to directly turn bone marrow stem cells into brain cells

TSRI scientists find way to directly turn bone marrow stem cells into brain cells

Integral Molecular releases MPS antibody discovery platform

Integral Molecular releases MPS antibody discovery platform

Third Rock Ventures announces formation of Jounce Therapeutics

Third Rock Ventures announces formation of Jounce Therapeutics

Dyax fourth quarter total revenues increase to $16.0 million

Dyax fourth quarter total revenues increase to $16.0 million

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

Trellis, OMT enter collaboration to generate human antibodies

Trellis, OMT enter collaboration to generate human antibodies

Scripps scientists discover new antibody-discovery technique

Scripps scientists discover new antibody-discovery technique

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.